Circulating Vitronectin Predicts Liver Injury and Mortality in Children With Sepsis: A Prospective Observational Study

Chunxia Wang, PhD¹,², Yun Cui, MD¹, Huijie Miao, MD¹, Ting Sun, MD¹, Ye Lu, MD¹, and Yucai Zhang, MD, PhD¹,²

Abstract
Vitronectin (VTN) is a key regulator of coagulation, but clinical relevance of serum VTN in pediatric sepsis remains poorly defined. The aim of this study was to assess the value of serum VTN level on pediatric intensive care unit (PICU) admission in children with sepsis. Pediatric patients with sepsis were enrolled from January 2018 to December 2018. The serum VTN levels were determined on PICU admission, and the association of serum VTN level with PICU mortality and organ dysfunction was assessed. Serum VTN levels were significantly lower in nonsurvivors compared with survivors, in patients with septic shock compared with patients with sepsis, or in patients with sepsis-associated acute liver injury (ALI) compared with patients without ALI. Serum VTN level was associated with PICU mortality (odds ratio [OR]: 0.958, 95% CI: 0.927-0.996; \( P = 0.010 \)) or ALI (OR: 0.956, 95% CI: 0.915-0.999; \( P = 0.046 \)), but not shock (OR: 0.996, 95% CI: 0.977-1.016; \( P = 0.716 \)). The area under receiver operating characteristic curve for VTN in predicting the occurrence of ALI during PICU stay and PICU mortality were 0.760 (95% CI: 0.627-0.893) and 0.737 (95% CI: 0.544-0.931), respectively. Moreover, VTN plus pediatric risk of mortality (PRISM) III had a better clinical utility according to decision curve analysis compared with VTN or PRISM III alone. These findings suggest that serum VTN level is associated with sepsis-associated ALI and PICU mortality, and VTN plus PRISM III is a powerful predictor of PICU mortality in pediatric patients with sepsis, which have a better clinical benefit compared with VTN or PRISM III alone.

Keywords
vitronectin, mortality, acute liver injury, sepsis, children

Date received: 13 April 2020; revised: 15 May 2020; accepted: 25 May 2020.

Introduction
Sepsis is a leading cause of death in patients with critically ill admitted to intensive care units.¹ Although clinical advancements in early identification and appropriate management to improve outcomes have taken place, the sepsis-associated mortality remains high. Pooled case fatality rates in pediatric severe sepsis and septic shock are higher in developing countries (31.7%) than in developed countries (19.3%).² In China, the hospital mortality of pediatric severe sepsis or septic shock is 18.8% or 80.8% of the cases comprise patients aged less than 5 years.³ Pathologically, uncontrolled activation of the coagulation cascade is a fundamental event that leads to diffuse microvascular thrombosis, multi-organ dysfunction, and death.³⁻⁶ The cross talk between thrombosis and inflammation supports the concept of a thrombo-inflammatory state correlates with septic severity and prognosis,⁷ and thrombus biomarkers such as D-dimer, fibrinogen (Fib), and platelet count are associated with the short-term adverse outcomes of patients with sepsis.⁷⁻⁹ However, it remains unclear whether specific indicators for thrombosis would be helpful in identifying patients with sepsis who are at an increased risk of death in the early onset of the condition, which is critical for risk identification and treatment decisions.

Vitronectin (VTN) is a multifunctional glycoprotein present in blood that acts as biological “superglue” and a key

¹ Department of Critical Care Medicine, Shanghai Children’s Hospital, Shanghai Jiao Tong University, Shanghai, China
² Institute of Pediatric Critical Care, Shanghai Jiao Tong University, Shanghai, China

Corresponding Author:
Yucai Zhang, Department of Critical Care Medicine, Shanghai Children’s Hospital, Institute of Pediatric Critical Care, Shanghai Jiao Tong University, No. 355 Luding Road, Putuo District, Shanghai 200062, China.
Email: zyucai2018@163.com
controller of mammalian tissue repair and remodeling. The concentration of VTN in the peripheral vasculature is high (200-400 ng/mL) and is involved in immune responses and the regulation of clot formation by binding to complement, heparin, and thrombin antithrombin III complexes. The interaction of VTN with plasminogen activation inhibitor-1 (PAI-1) exerts multiple deleterious effects that induce acute kidney injury (AKI) and exacerbate lung fibrosis in mice. High levels of PAI-1 are correlated with the severity and mortality of sepsis. Given the inhibitory effectiveness of VTN on PAI-1 activity during coagulation, we hypothesized that serum VTN level is a prognostic predictor for mortality in pediatric patients with sepsis.

To verify this hypothesis, we conducted a prospective observational study, in which we enrolled pediatric patients with sepsis to measure serum VTN levels on pediatric intensive care unit (PICU) admission, and then assessed the potential value in predicting the outcome and organ dysfunction in sepsis.

Materials and Methods

Study Design and Patient Characteristics

Patients with sepsis were enrolled, who were admitted to the PICU at Shanghai Children’s Hospital from January 2018 to December 2018. The diagnosis criteria for pediatric sepsis were based on the International Pediatric Sepsis Consensus Conference in 2005, and sepsis-associated liver injury is defined as referenced by Surviving Sepsis Campaign International Guidelines in 2012. The inclusion criteria included the following: (1) aged between 29 days and 18 years, (2) diagnosed with sepsis when admitted to PICU, and (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours. The exclusion criteria were as follows: (1) aged between 29 days and 18 years, (2) lack of the value of serum VTN levels, (3) the length of PICU stay for over 24 hours.

Blood Samples

The blood samples were collected within 1 hour after PICU admission in sterile vacutainer tubes for further analysis. Serum was obtained and stored at −80 °C for VTN determination.

Observational Variables

Demographic and clinical parameters were collected using a predesigned case report form. These parameters included age, gender, comorbidities, infection sites, pathogens, pediatric risk of mortality (PRISM) III score, ratio of mechanical ventilator support, and ratio of vasoactive agents needed. Etiology diagnosis was based on the epidemiological and clinical characteristics, the results of routine blood test including white blood cell and C-reactive protein level. Furthermore, procalcitonin and lipopolysaccharide determination were used to identify bacterial infection even Gram-negative bacterial infection. Blood culture was further used to identify the bacterial species. For virus diagnosis, the nucleic acid detection and antibody neutralization test were used in our center. In addition, 1-3-β-D-glucan test kit (fungi G test) was used for early diagnosis of fungi infection. Furthermore, if the conventional tests were failure to identify the pathogenic species, next-generation sequencing would be used. The laboratory parameters included lactate (Lac), international normalized ratio, activated partial thromboplastin time, Fib, alanine aminotransferase (ALT), total bilirubin (TBIL), lactate dehydrogenase, and γ-glutamyl transpeptidase. The outcome variables included the length of PICU stay, organ dysfunction during PICU hospitalization, and PICU survival status.

Serum VTN Analysis Using Enzyme-Linked Immunosorbent Assay

The concentration of serum VTN was determined using ELISA kit (Multi Sciences Co. Ltd, Cat No. 70-EK11992). The range of detection for VTN was from 0.25 to 16 ng/mL. Serum samples were diluted before detection.

Statistical Analyses

Continuous variables were presented as the median (interquartile range) for abnormal distribution data and mean ± standard deviation for normal distribution data. The Mann-Whitney U test or Student t test was used to compare the continuous variables with abnormally or normally distributed data, respectively. The χ2 test was used to compare the categorical data presented as percent or number. Correlation analysis was performed using linear regression. The associations between covariates and PICU mortality, shock, or acute liver injury (ALI) were estimated by multivariable logistic regression models. To assess the capacity of VTN to act as predictors of PICU mortality or sepsis-associated ALI, a receiver operating characteristic (ROC) curve was generated. To compare the clinical utility of VTN, PRISM III, or VTN plus PRISM III, decision curve analysis was performed as referenced. Data analyses were performed using STATA 15.0 MP. A value of P < .05 was considered statistically significant. All P values presented are 2 tailed.

Results

Baseline Characteristics of Patients

During a 1-year period, a total of 101 patients diagnosed with sepsis were eligible. Patient with advanced tumor (n = 1), lack of appropriate serum VTN levels (n = 5), congenital heart disease (n = 6), or severe primary diseases/heredity metabolic disease (n = 7) were excluded. Finally, 82 pediatric patients with sepsis were enrolled in this study (Figure 1).
The median age of patients was 18.5 (4-51) months and 52.4% of the enrolled patients were male (43/82). Respiratory failure was the most common comorbidity (61.0%), as well as respiratory tract was the most frequently infected site (48.8%). Of the patients with respiratory failure, 62.2% required mechanical ventilation (51/82), and 56.1% received vasoactive infusions (46/82). Among the 13 nonsurvivors, all patients (100%, 13/13) required mechanical ventilation and vasoactive agents. All nonsurvivors were complicated by multiple organ dysfunction syndromes (MODs) when sepsis was diagnosed (100%, 13/13). The PICU morbidity rate of pediatric sepsis was 15.9% (13/82). There were significant differences in PRISM III score ($P = .001$), complications with respiratory failure ($P = .002$), shock ($P = .005$), ALI ($P = .026$) or MODS ($P < .001$), and ratio of mechanical ventilator and vasoactive supporting agents ($P = .001$) between survivor (n = 69) and nonsurvivor (n = 13) individuals (Table 1).

**Table 1. Baseline Characteristics of Patients With Sepsis.**

| Characteristics | Total (n = 82) | Survivor (n = 69) | Nonsurvivor (n = 13) | $P$ value |
|-----------------|---------------|------------------|---------------------|-----------|
| Age (month)     | 18.5 (4-51)   | 19 (5-51)        | 7 (4-45)            | .643      |
| Gender (male, %)| 43 (52.4)     | 37 (53.6)        | 6 (46.2)            | .621      |
| PRISM III       | 10 (3-12)     | 8.5 (3-11)       | 13 (7-18)           | .014      |
| Complications   |               |                  |                     |           |
| Respiratory failure, n (%) | 50 (61.0) | 37 (53.6) | 13 (100) | .002 |
| Shock, n (%)    | 40 (48.8)     | 29 (42.0)        | 11 (84.6)           | .005      |
| Gastrointestinal disorder, n (%) | 31 (37.8) | 26 (37.7) | 5 (38.5) | .958 |
| Liver injury, n (%) | 10 (12.2) | 6 (8.7) | 4 (30.8) | .026 |
| Acute kidney injury, n (%) | 14 (17.1) | 10 (14.5) | 4 (30.8) | .153 |
| MODS, n (%)     | 39 (47.6)     | 26 (37.7)        | 13 (100)            | <.001     |
| Primary infection site |           |                  |                     |           |
| Respiratory tract, n (%) | 40 (48.8) | 32 (46.4) | 8 (61.5) | .207 |
| Gastrointestinal, n (%) | 20 (24.4) | 19 (27.5) | 1 (7.7) |         |
| Urine system, n (%) | 1 (1.2) | 1 (1.4) | 0 (0) |         |
| Skin/soft tissue/bloodstream, n (%) | 13 (15.9) | 9 (13.0) | 4 (30.8) |         |
| Central nervous system, n (%) | 7 (8.5) | 7 (10.1) | 0 (0) |         |
| Pathogen        |               |                  |                     | .156      |
| Bacterial, n (%) | 45 (54.9)     | 37 (53.6)        | 8 (61.5)            |           |
| Virus, n (%)    | 24 (29.3)     | 21 (30.4)        | 3 (23.1)            |           |
| Others, n (%)   | 7 (8.5)       | 5 (7.2)          | 2 (15.4)            |           |
| Mechanical ventilator, n (%) | 51 (62.2) | 38 (55.1) | 13 (100) | .355 |
| Vasoactive agents, n (%) | 46 (56.1) | 33 (47.8) | 13 (100) | .001 |
| Length of PICU stay, day | 5 (3-9) | 5.5 (2-10) | 4 (3-12) | .553 |

Abbreviations: MODS, multiple organ dysfunction syndrome; PICU, pediatric intensive care unit; PRISM III, pediatric risk of mortality III.

The median age of patients was 18.5 (4-51) months and 52.4% of the enrolled patients were male (43/82). Respiratory failure was the most common comorbidity (61.0%), as well as respiratory tract was the most frequently infected site (48.8%). Of the patients with respiratory failure, 62.2% required mechanical ventilation (51/82), and 56.1% received vasoactive infusions (46/82). Among the 13 nonsurvivors, all patients (100%, 13/13) required mechanical ventilation and vasoactive agents. All nonsurvivors were complicated by multiple organ dysfunction syndromes (MODs) when sepsis was diagnosed (100%, 13/13). The PICU morbidity rate of pediatric sepsis was 15.9% (13/82). There were significant differences in PRISM III score ($P = .001$), complications with respiratory failure ($P = .002$), shock ($P = .005$), ALI ($P = .026$) or MODS ($P < .001$), and ratio of mechanical ventilator and vasoactive supporting agents ($P = .001$) between survivor (n = 69) and nonsurvivor (n = 13) individuals (Table 1).

**Serum VTN Levels Are Low in Nonsurvivors or Patients With Septic Shock, Sepsis-Associated ALI**

Given the coagulation disorder might contribute to multiple organ dysfunction during sepsis, the association between
serum VTN levels and organ dysfunction was analyzed. The results indicated that serum VTN levels on PICU admission were lower in nonsurvivors (19.8 [11.8-43.0] μg/mL vs 54.0 [29.7-67.9] μg/mL, \( P = .022 \); Figure 2A), in patients complicated by ALI (26.2 [13.2-42.2] μg/mL vs 54.6 [29.3-70.9] μg/mL, \( P = .007 \); Figure 2B) or septic shock (42.6 [24.1-60.2] μg/mL vs 58.6 [37.1-76.2] μg/mL, \( P = .036 \); Figure 2C), but there were no differences among other subgroups with respiratory failure, AKI, gastrointestinal dysfunction, or MODS (all \( P > .05 \); Table 2).

**Table 2.** Comparison of Serum Vitronectin Levels in Patients Complicated by Different Organ Dysfunction.

| Organ dysfunction       | No Case number | VTN (μg/mL) | Yes Case number | VTN (μg/mL) | \( P \) value |
|-------------------------|----------------|-------------|-----------------|-------------|--------------|
| Shock                   | 42             | 58.6 (37.1-76.2) | 40             | 42.6 (24.1-60.2) | .036         |
| Respiratory failure     | 32             | 50.4 (25.9-63.6) | 50             | 49.6 (25.5-68.6) | .846         |
| AKI                     | 68             | 54.6 (29.1-69.4) | 14             | 30.6 (17.7-51.1) | .125         |
| ALI                     | 72             | 54.6 (29.3-70.9) | 10             | 26.2 (13.2-42.2) | .007         |
| Gastrointestinal dysfunction | 51         | 54.0 (28.8-71.5) | 31             | 42.6 (22.7-60.9) | .247         |
| MODS                    | 43             | 55.2 (28.4-70.2) | 39             | 43.0 (25.4-64.3) | .314         |
| 28-day death            | 69             | 54.0 (29.7-67.9) | 13             | 19.8 (11.8-43.0) | .022         |

Abbreviations: AKI, acute kidney injury; ALI, acute liver injury; MODS, multiple organ dysfunction syndrome; VTN, vitronectin.

**Table 3.** The Laboratory Indexes of Patients With Sepsis.

| Variables      | Total (n = 82) | Survivor (n = 69) | Nonsurvivor (n = 13) | \( P \) |
|----------------|----------------|-------------------|----------------------|--------|
| Lac (mmol/L)   | 1.1 (0.75-2.0) | 1.1 (0.75-1.85)   | 1.45 (0.8-2.3)       | .473   |
| INR            | 1.14 (1.06-1.24) | 1.13 (1.06-1.24) | 1.16 (1.07-1.25)    | .436   |
| APTT(s)        | 36.8 (31.4-43.1) | 37.95 (32.25-42.65) | 35.1 (30.5-44.9)    | .787   |
| Fib (g/L)      | 2.79 (1.79-4.09) | 2.82 (1.91-4.29) | 2.21 (1.04-2.86)    | .131   |
| ALT (U/L)      | 20 (14-47)        | 19 (13-43)        | 29 (16-71)          | .112   |
| TBIL (μmol/L)  | 7.57 (4.68-15.44) | 7.21 (4.68-12.3)  | 8.73 (4.79-17.94)   | .281   |
| LDH (U/L)      | 352 (288-478)     | 350.5 (280-466)   | 414 (317-665)       | .375   |

Abbreviations: ALT, alanine transaminase; APTT, activated partial thromboplastin time; Fib, fibrinogen; INR, international normalized ratio; Lac, lactate; LDH, lactate dehydrogenase; TBIL, total bilirubin; \( \gamma \)-GT, \( \gamma \)-glutamyl transpeptidase.

**Level of Circulating VTN Is Linearly Correlated With Blood Fib Level**

Serum VTN levels were specifically decreased in patients with septic shock or sepsis-associated ALI; therefore, we compared the values of indicators for shock and liver function on PICU admission between survivors and nonsurvivors (Table 3). Lactate levels on PICU admission in nonsurvivors were higher tendency than that in survivors without statistic difference (\( P = .473 \), Table 3), and ALT levels were mildly increased.
Table 5. Multivariate Logistic Analysis About the Association Between Laboratory Parameters and PICU Mortality or Organ Dysfunction in Patients With Sepsis.

| Variables      | OR     | 95% CI          | P     |
|----------------|--------|-----------------|-------|
| PICU mortality | VTN    | 0.958           | 0.927-0.990 | .010 |
|                | PRISM III | 1.187          | 1.042-1.353  | .010 |
| Shock          | VTN    | 0.996           | 0.977-1.016  | .716 |
|                | Lac    | 1.995           | 1.110-3.585  | .021 |
| Acute live injury | VTN   | 0.956           | 0.915-0.999  | .046 |
|                | TBIL   | 1.030           | 0.990-1.072  | .140 |
|                | ALT    | 1.035           | 1.004-1.067  | .025 |

Abbreviations: ALT, alanine transaminase; Lac, lactate; OR, odds ratio; PICU, pediatric intensive care unit; PRISM III, pediatric risk of mortality III; TBIL, total bilirubin; VTN, vitronectin.

Figure 3. Correlation analysis of serum vitronectin with fibrinogen levels.

Serum VTN Level Is Associated With PICU Mortality and Sepsis-Associated ALI in Pediatric Patients With Sepsis

Based on the clear correlations between VTN and shock, sepsis-associated ALI, and PICU mortality, we hypothesized that serum VTN measurements could predict the occurrence of shock, sepsis-associated ALI, and poor outcome in pediatric patients with sepsis. Multivariate logistic analysis indicated that serum VTN level and PRISM III score were independent factors for PICU mortality prediction (odds ratio [OR]: 0.958 [95% CI: 0.927-0.990], P = .010; OR: 1.187 [95% CI: 1.042-1.353], P = .010; respectively; Table 5). Furthermore, serum VTN and ALT levels were significantly associated with the occurrence of sepsis-associated ALI (0.956 [0.915-0.999], P = .046; OR: 1.035 [95% CI: 1.004-1.067], P = .025; respectively; Table 5). However, serum VTN level was not independent factor for shock (OR: 0.996 [95% CI: 0.977-1.016], P = .716) in pediatric sepsis adjusted by Lac (OR: 1.995 [95% CI: 1.110-3.585], P = .021; Table 5).

Receiver operating characteristic analysis was further used to evaluate the potential value of serum VTN level for predicting PICU mortality and sepsis-associated ALI. Given that both serum VTN level and PRISM III score are associated with PICU mortality in pediatric sepsis, the predictive utility of VTN or PRISM III alone and VTN plus PRISM III was analyzed and compared. The area under the ROC curve (AUC) for VTN plus PRISM III was 0.802 (95% CI: 0.655-0.949), which is superior to the predictive utility of VTN alone (AUC = 0.737 [95% CI: 0.544-0.931]) or PRIM III alone (AUC = 0.719 [95% CI: 0.548-0.890]; P = .054; Figure 4A). For assessing PICU mortality, the specificity was 87.88% and sensitivity was 53.85% at a cutoff value of 20 μg/mL (Figure 4A). According to the result of decision curve analysis, it appears that the VTN + PRISM III model was superior to the simple model across a wide range of threshold probabilities, with the highest difference at a threshold probability around 0.6. At that threshold, the net benefit was 0.015 for the PRISM III model and 0.075 for the VTN + PRISM III model (Figure 4B). For predicting sepsis-associated ALI, the AUC of serum VTN level for predicting ALI occurrence was 0.737 (95% CI: 0.544-0.931) with a sensitivity of 90.00% and a specificity of 59.72% with a threshold cutoff value of 47 μg/mL (Figure 4C).

Discussion

Coagulation disorder is a well-known key characteristic of sepsis pathophysiology, but an adequate laboratory index for
its early assessment is not available. To the best of our knowledge, this is the first study to report that serum VTN level on PICU admission is associated with the occurrence of ALI and PICU mortality in pediatric patients with sepsis, and serum VTN level plus PRISM III is a predictor of PICU mortality in pediatric sepsis.

Liver injury is a common risk factor for poor mortality in patients with sepsis. The incidence rate of sepsis-associated ALI in patients enrolled in this study during a 1-year period was 12.2% (10/82), which is consistent with our previous retrospective study on the sepsis-associated ALI incidence rate (9.7%, 72/745)\(^2\); however, the incidence rate observed in the current study was lower than that of a recent study conducted in Southwest China (19.6%).\(^3\) The PICU mortality of patients with sepsis-associated ALI was 40% in the present study, which is consistent with the observation of our previous retrospective study (36.1% [26/72]).\(^2\) The mortality rate was significantly higher in patients with sepsis-associated ALI (40%, 4/10) than in patients without ALI (12.5%, 9/72) in our present study. Therefore, early identification of liver injury during sepsis needs more clinical and research attention and will be helpful for developing strategies for improving the outcome of sepsis.

Inflammation-induced changes in coagulation play a pivotal role in the pathogenesis of sepsis, and inflammation and coagulation interact with each other and are involved in sepsis-induced organ failure.\(^2\) Platelet function, pro- and anticoagulant proteins concentrations, and fibrinolytic pathway protein concentrations are developmentally regulated in the liver. Therefore, coagulation disorders result in liver dysfunction. Early assessment of coagulation disorders could be useful for early identification of liver injury. Increased PAI-1 or activation of thrombin-activatable fibrinolysis inhibitor is hallmark of sepsis,\(^2\) and the polymorphisms of PAI-1 might be related to patient susceptibility to sepsis. Given the important role of VTN as an inhibitor of PAI-1 through the direct binding of PAI-1, changes in serum VTN levels might be superior to PAI-1 as a predictor for coagulation disorders. To the best of our knowledge, this is the first study to investigate the role of serum VTN level in predicting sepsis-associated ALI occurrence.

Hypercoagulability and endothelial injury can cause disseminated intravascular coagulation (DIC) and is found in 25% to 50% of patients with sepsis, which may contribute to organ failure and high patient mortality.\(^5\) D-dimer, as a biomarker for early identification of DIC,\(^9\) was associated with the prognosis of patients with sepsis.\(^9\) High level of PAI-1 was also associated with the severity and mortality of sepsis.\(^14,15\) Consistently, as an inhibitor of PAI-1, serum VTN levels were significantly lower in nonsurvivors than survivors on PICU admission, which was associated with PICU mortality. Our previous study indicated that a TBIL value >64.5 \(\mu\)mol/L within 72 hours after PICU admission is an independent risk factor for mortality in patients with sepsis-associated ALI.\(^2\) In the present study, the level of TBIL on PICU admission was 11.995 \(\mu\)mol/L (95% CI: 8.34-77.95) in patients with sepsis-associated ALI, and it was not associated with prognosis of pediatric sepsis. These results suggested that serum VTN is an earlier prognostic predictor compared with TBIL. More importantly, we found that serum VTN level plus PRISM III got a higher AUC and a better clinical benefit for predicting PICU mortality than PRISM III alone. At the highest difference at a threshold probability around 0.6, the net benefit was 0.015 for the PRISM III model, and 0.075 for the VTN + PRISM III model. This means that one can administrate about 7.5-1.5 = 6 more profitable assessment (of 100 patients) when using the VTN + PRISM III model rather than the PRISM III model to predict PICU mortality. This clinical benefit of serum VTN in predicting mortality of pediatric sepsis needs more attention in the future.

There were a few limitations in this study. As a prospective observational study, the sample size was small, and the conclusions drawn from the present pediatric population need further investigation in a larger population. For early detection of coagulation changes in pediatric patients, blood samples were collected on PICU admission, but the changes about serum VTN levels during PICU hospitalization were lack. In addition, the values of other indicators for coagulation such as PAI-1 and D-dimer were unavailable due to the limited volume of blood samples collected from infants and younger children enrolled in this study. Nevertheless, we believe our results show that

---

**Figure 4.** ROC and decision curve analysis (DCA) for predicting PICU mortality or acute liver injury (ALI). (A) ROC analysis of VTN, PRISM III, or VTN plus PRISM III for PICU mortality. (B) DCA analysis of VTN, PRISM III, or VTN plus PRISM III for PICU mortality (C) ROC analysis for ALI. PICU, pediatric intensive care unit; PRISM, pediatric risk of mortality; ROC, receiver operating characteristic; VTN, vitronectin.
serum VTN level can serve as an early-response marker and effective predictor for sepsis-associated ALI or PICU mortality in pediatric patients with sepsis.

In summary, serum VTN level is associated with occurrence of sepsis-associated ALI and PICU mortality. Serum VTN level plus PRISM III is a powerful predictor for PICU mortality in children with sepsis, which have a better clinical benefit compared with VTN or PRISM III alone.

Authors’ Note
C.W. and Y.Z. conceived and designed the study. C.W., Y.C., H.M., T.S., and Y.L. collected and analyzed data. C.W., Y.C., and Y.Z. contributed analysis tools and discussion. C.W. and Y.Z. wrote the paper. Our present study was a prospective observational study. The datasheet for this study is available from the corresponding author upon reasonable request. This study was approved by Ethical Committee of Children’s Hospital Affiliated to Shanghai Jiao Tong University and conducted in accordance with provisions of the Declaration of Helsinki (Approval number: 2018R039-F01). The written informed consents were obtained from all patients’ relatives.

Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This study was supported by the Science and Technology Commission of Shanghai Municipality (18411951000), the Shanghai Municipal Education Commission—Gaofeng Clinical Medicine Grant support (20171928). C.W. is supported by Talents Program of Shanghai Jiao Tong University School of Medicine (17XJ11018).

ORCID ID
Yucai Zhang https://orcid.org/0000-0002-4905-3600

References
1. Fleischmann C, Scherag A, Adhikari NK, et al. Assessment of global incidence and mortality of hospital-treated sepsis. Current estimates and limitations. Am J Respir Crit Care Med. 2016;193(3):259-272.
2. Tan B, Wong JJ, Sultana R, et al. Global case-fatality rates in pediatric severe sepsis and septic shock: a systematic review and meta-analysis. JAMA Pediatr. 2019;173(4):352-362.
3. Xiao C, Wang S, Fang F, et al. Epidemiology of pediatric severe sepsis in main PICU centers in Southwest China. Pediatr Crit Care Med. 2019;20(12):1118-1125.
4. Levi M, Schultz M, van der Poll T. Sepsis and thrombosis. Semin Thromb Hemost. 2013;39(5):559-566.
5. Levi M, van der Poll T. Coagulation and sepsis. Thromb Res. 2017;149:38-44.
6. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Sepsis, thrombosis and organ dysfunction. Thromb Res. 2012;129(3):290-295.
7. Lupu F, Keshari RS, Lambris JD, Coggeshall KM. Crosstalk between the coagulation and complement systems in sepsis. Thromb Res. 2014;133(suppl 1):S28-S31.
8. Moore JX, Zakai NA, Mahalingam M, et al. Hemostasis biomarkers and risk of sepsis: the REGARDS cohort. J Thromb Haemost. 2016;14(11):2169-2176.
9. Rodelo JR, De la Rosa G, Valencia ML, et al. D-dimer is a significant prognostic factor in patients with suspected infection and sepsis. Am J Emerg Med. 2012;30(9):1991-1999.
10. Schwartz I, Seger D, Shaltiel S. Vitronectin. Int J Biochem Cell Biol. 1999;31(5):539-544.
11. Izumi M, Yamada KM, Hayashi M. Vitronectin exists in two structurally and functionally distinct forms in human plasma. Biochim Biophys Acta. 1989;990(2):101-108.
12. Gupta KK, Donahue DL, Sandoval-Cooper MJ, Castellino FJ, Plophis VA. Abrogation of plasminogen activator inhibitor-1-vitronectin interaction ameliorates acute kidney injury in murine endotoxemia. PLoS One. 2015;10(3):e0120728.
13. Courey AJ, Horowitz JC, Kim KK, et al. The vitronectin-binding function of PAI-1 exacerbates lung fibrosis in mice. Blood. 2011;118(8):2313-2321.
14. Hoshino K, Kitamura T, Nakamura Y, et al. Usefulness of plasminogen activator inhibitor-1 as a predictive marker of mortality in sepsis. J Intensive Care. 2017;5:42.
15. Lorente L, Martin MM, Borrego-Leon JM, et al. Sustained high plasma plasminogen activator inhibitor-1 levels are associated with severity and mortality in septic patients. Thromb Res. 2014;134(1):182-186.
16. Goldstein B, Giroir B, Randolph A. International Consensus Conference on Pediatric Sepsis. International pediatric sepsis consensus conference: definitions for sepsis and organ dysfunction in pediatrics. Pediatr Crit Care Med. 2005;6(1):2-8.
17. Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: International Guidelines for Management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):630-637.
18. Zhang Z. Univariate description and bivariate statistical inference: the first step delving into data. Ann Transl Med. 2016;4(5):91.
19. Zhang Z, Rousson V, Lee WC, et al. Decision curve analysis: a technical note. Ann Transl Med. 2018;6(15):308.
20. Nessler N, Launey Y, Aninat C, et al. Liver dysfunction is associated with long-term mortality in septic shock. Am J Respir Crit Care Med. 2016;193(3):335-337.
21. Cui Y, Shan Y, Chen R, Wang C, Zhang Y. Elevated serum total bilirubin level is associated with poor outcomes in pediatric patients with sepsis-associated liver injury. Can J Infect Dis Med Microbiol. 2018;2018:4591729.
22. Esmon CT. Interactions between the innate immune and blood coagulation systems. Trends Immunol. 2004;25(10):536-542.
23. Gando S, Saitoh D, Ogura H, et al. A multicenter, prospective validation study of the Japanese Association for Acute Medicine disseminated intravascular coagulation scoring system in patients with severe sepsis. Crit Care. 2013;17(3):R111.
24. Semeraro F, Colucci M, Caironi P, et al. Platelet drop and fibrinolytic shutdown in patients with sepsis. Crit Care Med. 2018;46(3):e221-e228.
25. Chi YF, Chai JK, Yu YM, et al. Association between PAI-1 polymorphisms and plasma PAI-1 level with sepsis in severely burned patients. *Genet Mol Res*. 2015;14(3):10081-10086.

26. Lorente L, Martin MM, Borreguero-Leon JM, et al. The 4G/4G Genotype of PAI-1 polymorphism is associated with higher plasma PAI-1 concentrations and mortality in patients with severe sepsis. *PLoS One*. 2015;10(6):e0129565.

27. Gando S. Role of fibrinolysis in sepsis. *Semin Thromb Hemost*. 2013;39(4):392-399.

28. Semeraro N, Ammollo CT, Semeraro F, Colucci M. Coagulopathy of acute sepsis. *Semin Thromb Hemost*. 2015;41(6):650-658.

29. Sharma A, Sikka M, Gomber S, Sharma S. Plasma fibrinogen and D-dimer in children with sepsis: a single-center experience. *Iran J Pathol*. 2018;13(2):272-275.

30. Schwameis M, Steiner MM, Schoergenhofer C, et al. D-dimer and histamine in early stage bacteremia: a prospective controlled cohort study. *Eur J Intern Med*. 2015;26(10):782-786.